Repligen to buy BioLife Solutions in $1.5 billion deal
RGEN•Repligen to expand into cell therapy with BioLife Solutions deal
July 22 (Reuters) - Repligen Corp RGEN.O said on Wednesday it would buy BioLife Solutions BLFS.O, a cell-and-gene-therapy tools maker, in a deal valued at about $1.5 billion to expand its presence in the fast-growing cell therapy market.
